Skip to main content
Journal cover image

Dose dependent effects of cardiac beta2 adrenoceptor gene therapy.

Publication ,  Journal Article
Jones, JM; Wilson, KH; Steenbergen, C; Koch, WJ; Milano, CA
Published in: J Surg Res
November 2004

BACKGROUND: Adenoviral-mediated gene transfer during cardiopulmonary bypass (CPB) achieves efficient myocardial transgene expression. The optimal vector dose required to produce not only increased beta adrenoceptor (betaAR) density but, more importantly, enhanced left ventricular (LV) function is unknown. In addition, it is unclear if absent extracardiac expression in preliminary studies represented cardiac specific, as opposed to selective gene delivery, as a consequence of low vector doses. MATERIALS AND METHODS: Adenoviral vector encoding the human beta(2) adrenoceptor (Adeno-beta(2)AR) was delivered to cardioplegic arrested hearts of neonatal piglets during CPB in three doses ranging from 5 x 10(11) total viral particles (tvp) to 2 x 10(12) tvp. Control animals received adenoviral vector encoding beta galactosidase (Adeno-betagal) or PBS (PBS). LV and liver betaAR density and in vivo LV function were assessed 5 days later. RESULTS: Elevated LV betaAR density was present after delivery of Adeno-beta(2)AR at all doses. Piglets which received 5 x 10(11) tvp and 1 x 10(12) tvp Adeno-beta(2)AR demonstrated enhanced LV dP/dt(max) but in those receiving 2 x 10(12) tvp LV dP/dt(max) was unchanged. Moreover, at this higher dose of adenoviral vector the detrimental effects of cardiac inflammation and extracardiac gene overexpression became apparent. CONCLUSIONS: Although the highest increase in cardiac betaAR density occurred after high-dose Adeno-beta(2)AR, LV dP/dt(max) was not enhanced. Moreover, significant extracardiac gene expression was present at this dose, emphasizing the need for careful dose response studies in gene therapy. However, cardiac selective beta(2)AR overexpression does occur following adenoviral vector delivery during CPB and cardioplegic arrest resulting in enhanced LV dP/dt(max).

Duke Scholars

Published In

J Surg Res

DOI

ISSN

0022-4804

Publication Date

November 2004

Volume

122

Issue

1

Start / End Page

113 / 120

Location

United States

Related Subject Headings

  • Ventricular Function, Left
  • Treatment Outcome
  • Swine
  • Surgery
  • Receptors, Adrenergic, beta-2
  • Myocardium
  • Humans
  • Hemodynamics
  • Heart Arrest, Induced
  • Genetic Vectors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jones, J. M., Wilson, K. H., Steenbergen, C., Koch, W. J., & Milano, C. A. (2004). Dose dependent effects of cardiac beta2 adrenoceptor gene therapy. J Surg Res, 122(1), 113–120. https://doi.org/10.1016/j.jss.2004.06.009
Jones, J Mark, Katrina H. Wilson, Charles Steenbergen, Walter J. Koch, and Carmelo A. Milano. “Dose dependent effects of cardiac beta2 adrenoceptor gene therapy.J Surg Res 122, no. 1 (November 2004): 113–20. https://doi.org/10.1016/j.jss.2004.06.009.
Jones JM, Wilson KH, Steenbergen C, Koch WJ, Milano CA. Dose dependent effects of cardiac beta2 adrenoceptor gene therapy. J Surg Res. 2004 Nov;122(1):113–20.
Jones, J. Mark, et al. “Dose dependent effects of cardiac beta2 adrenoceptor gene therapy.J Surg Res, vol. 122, no. 1, Nov. 2004, pp. 113–20. Pubmed, doi:10.1016/j.jss.2004.06.009.
Jones JM, Wilson KH, Steenbergen C, Koch WJ, Milano CA. Dose dependent effects of cardiac beta2 adrenoceptor gene therapy. J Surg Res. 2004 Nov;122(1):113–120.
Journal cover image

Published In

J Surg Res

DOI

ISSN

0022-4804

Publication Date

November 2004

Volume

122

Issue

1

Start / End Page

113 / 120

Location

United States

Related Subject Headings

  • Ventricular Function, Left
  • Treatment Outcome
  • Swine
  • Surgery
  • Receptors, Adrenergic, beta-2
  • Myocardium
  • Humans
  • Hemodynamics
  • Heart Arrest, Induced
  • Genetic Vectors